Skip to main content

Table 2 Results of pooled analysis for AXIN2 Polymorphism and cancer susceptibility

From: New insights of the correlation between AXIN2 polymorphism and cancer risk and susceptibility: evidence from 72 studies

Polymorphism Comparison Subgroup N PH PZ PAdjust OR & 95%CI (Random) OR & 95%CI (Fixed)
rs11079571 B vs. A Overall 3 < 0.001 0.005 0.025* 0.459(0.266–0.794) 0.539(0.478–0.609)
rs11079571 BB vs. AA Overall 3 0.001 < 0.001 < 0.001* 0.2(0.085–0.469) 0.22(0.164–0.295)
rs11079571 BA vs. AA Overall 3 0.081 < 0.001 < 0.001* 0.322(0.192–0.54) 0.292(0.216–0.394)
rs11079571 BB + BA vs. AA Overall 3 0.08 < 0.001 < 0.001* 0.265(0.162–0.433) 0.249(0.189–0.33)
rs11079571 BB vs. BA+ AA Overall 3 < 0.001 0.022 0.11 0.436(0.215–0.887) 0.619(0.531–0.723)
rs11079571 B vs. A Asian 2 0.002 0.001 0.005* 0.351(0.191–0.646) 0.407(0.345–0.479)
rs11079571 BB vs. AA Asian 2 0.007 < 0.001 < 0.001* 0.135(0.045–0.407) 0.178(0.127–0.251)
rs11079571 BA vs. AA Asian 2 0.416 < 0.001 < 0.001* 0.246(0.174–0.346) 0.247(0.175–0.348)
rs11079571 BB + BA vs. AA Asian 2 0.575 < 0.001 < 0.001* 0.216(0.157–0.297) 0.215(0.156–0.295)
rs11079571 BB vs. BA+ AA Asian 2 < 0.001 0.083 0.415 0.311(0.083–1.166) 0.463(0.368–0.582)
rs11079571 B vs. A Breast Cancer 2 < 0.001 0.148 0.74 0.446 (0.150–1.332) 0.594(0.507–0.697)
rs11079571 BB vs. AA Breast Cancer 2 < 0.001 0.056 0.28 0.182(0.032–1.047) 0.209(0.133–0.329)
rs11079571 BA vs. AA Breast Cancer 2 0.289 < 0.001 < 0.001* 0.419(0.255–0.689) 0.416(0.261–0.662)
rs11079571 BB + BA vs. AA Breast Cancer 2 0.041 0.009 0.045* 0.294(0.118–0.734) 0.285(0.184–0.441)
rs11079571 BB vs. BA+ AA Breast Cancer 2 < 0.001 0.202 1 0.356(0.073–1.74) 0.63(0.52–0.764)
rs1133683 B vs. A Overall 6 < 0.001 0.664 1.000 1.076(0.773–1.498) 1.14(1.021–1.273)
rs1133683 BB vs. AA Overall 6 < 0.001 0.005 0.025* 0.258(0.101–0.657) 0.391(0.284–0.539)
rs1133683 BA vs. AA Overall 6 < 0.001 0.036 0.18 2.079(1.048–4.126) 2.298(1.948–2.71)
rs1133683 BB + BA vs. AA Overall 6 < 0.001 0.1 0.5 1.78(0.895–3.538) 1.962(1.673–2.301)
rs1133683 BB vs. BA+ AA Overall 6 < 0.001 < 0.001 < 0.001* 0.162(0.08–0.328) 0.206(0.152–0.278)
rs1133683 B vs. A Asian 5 < 0.001 0.2 1.000 1.212(0.904–1.625) 1.25(1.11–1.408)
rs1133683 BB vs. AA Asian 5 < 0.001 0.026 0.13 0.283(0.093–0.858) 0.469(0.329–0.67)
rs1133683 BA vs. AA Asian 5 < 0.001 0.01 0.05 2.51(1.247–5.052) 2.627(2.203–3.132)
rs1133683 BB + BA vs. AA Asian 5 < 0.001 0.025 0.125 2.186(1.105–4.322) 2.283(1.926–2.707)
rs1133683 BB vs. BA+ AA Asian 5 < 0.001 < 0.001 < 0.001* 0.154(0.062–0.383) 0.21(0.15–0.295)
rs1133683 B vs. A PB 4 < 0.001 0.828 1.000 1.051(0.67–1.651) 1.146(1.01–1.302)
rs1133683 BB vs. AA PB 4 0.006 0.001 0.005* 0.256(0.113–0.584) 0.349(0.241–0.504)
rs1133683 BA vs. AA PB 4 < 0.001 0.118 0.59 2.112(0.827–5.395) 2.541(2.093–3.084)
rs1133683 BB + BA vs. AA PB 4 < 0.001 0.23 1.000 1.773(0.696–4.515) 2.142(1.777–2.582)
rs1133683 BB vs. BA+ AA PB 4 0.045 < 0.001 < 0.001* 0.16(0.086–0.297) 0.184(0.13–0.259)
rs1133683 B vs. A HB 2 0.004 0.72 1.000 1.127(0.587–2.163) 1.12(0.895–1.401)
rs1133683 BB vs. AA HB 2 < 0.001 0.46 1.000 0.265(0.008–8.979) 0.556(0.291–1.062)
rs1133683 BA vs. AA HB 2 < 0.001 0.249 1.000 2.001(0.615–6.508) 1.788(1.305–2.45)
rs1133683 BB + BA vs. AA HB 2 < 0.001 0.361 1.000 1.782(0.515–6.161) 1.572(1.159–2.132)
rs1133683 BB vs. BA+ AA HB 2 < 0.001 0.186 0.93 0.166(0.012–2.381) 0.297(0.158–0.559)
rs1133683 B vs. A Lung Cancer 2 0.016 0.767 1.000 1.071(0.68–1.687) 1.196(1.023–1.399)
rs1133683 BB vs. AA Lung Cancer 2 0.228 0.008 0.04* 0.491(0.263–0.918) 0.53(0.333–0.845)
rs1133683 BA vs. AA Lung Cancer 2 < 0.001 0.317 1.000 2.143(0.482–9.522) 2.695(2.109–3.442)
rs1133683 BB + BA vs. AA Lung Cancer 2 < 0.001 0.387 1.000 1.888(0.448–7.959) 2.36(1.86–2.995)
rs1133683 BB vs. BA+ AA Lung Cancer 2 0.39 < 0.001 < 0.001* 0.21(0.136–0.325) 0.212(0.138–0.328)
rs1133683 B vs. A Y 5 < 0.001 0.898 1.000 1.028(0.673–1.571) 1.036(0.899–1.193)
rs1133683 BB vs. AA Y 5 < 0.001 0.008 0.04* 0.211(0.067–0.666) 0.293(0.195–0.44)
rs1133683 BA vs. AA Y 5 < 0.001 0.14 0.7 1.767(0.83–3.762) 1.753(1.434–2.142)
rs1133683 BB + BA vs. AA Y 5 < 0.001 0.287 1.000 1.512(0.706–3.241) 1.499(1.236–1.818)
rs1133683 BB vs. BA+ AA Y 5 < 0.001 < 0.001 < 0.001* 0.152(0.057–0.405) 0.215(0.146–0.315)
rs2240308 B vs. A Overall 20 < 0.001 0.402 1.000 0.949(0.841–1.072) 0.962(0.906–1.02)
rs2240308 BB vs. AA Overall 19 < 0.001 0.722 1.000 0.952(0.726–1.248) 0.966(0.849–1.1)
rs2240308 BA vs. AA Overall 19 0.016 0.089 0.445 0.887(0.773–1.018) 0.915(0.834–1.004)
rs2240308 BB + BA vs. AA Overall 19 < 0.001 0.176 0.88 0.895(0.763–1.051) 0.923(0.846–1.007)
rs2240308 BB vs. BA+ AA Overall 19 < 0.001 0.963 1.000 1.005(0.811–1.246) 1.006(0.895–1.13)
rs2240308 B vs. A Asian 15 0.01 0.017 0.085 0.867(0.772–0.974) 0.879(0.815–0.947)
rs2240308 BB vs. AA Asian 15 0.019 0.072 0.36 0.799(0.626–1.021) 0.806(0.686–0.946)
rs2240308 BA vs. AA Asian 15 0.268 0.002 0.01* 0.828(0.731–0.939) 0.84(0.753–0.937)
rs2240308 BB + BA vs. AA Asian 15 0.066 0.004 0.02* 0.811(0.704–0.934) 0.835(0.754–0.926)
rs2240308 BB vs. BA+ AA Asian 15 0.053 0.273 1.000 0.889(0.721–1.097) 0.874(0.754–1.013)
rs2240308 B vs. A Caucasian 5 < 0.001 0.138 0.69 1.228(0.936–1.61) 1.119(1.016–1.233)
rs2240308 BB vs. AA Caucasian 4 < 0.001 0.082 0.41 2.069(0.912–4.692) 1.375(1.101–1.716)
rs2240308 BA vs. AA Caucasian 4 0.044 0.224 1.000 1.253(0.871–1.801) 1.141(0.957–1.36)
rs2240308 BB + BA vs. AA Caucasian 4 0.002 0.143 0.715 1.421(0.888–2.274) 1.198(1.014–1.414)
rs2240308 BB vs. BA+ AA Caucasian 4 0.001 0.112 0.56 1.6(0.896–2.858) 1.277(1.053–1.548)
rs2240308 B vs. A PB 12 < 0.001 0.894 1.000 0.987(0.815–1.195) 0.944(0.871–1.022)
rs2240308 BB vs. AA PB 12 < 0.001 0.955 1.000 1.012(0.67–1.529) 0.919(0.777–1.087)
rs2240308 BA vs. AA PB 12 0.064 0.364 1.000 0.924(0.78–1.096) 0.913(0.81–1.028)
rs2240308 BB + BA vs. AA PB 12 < 0.001 0.644 1.000 0.949(0.762–1.183) 0.911(0.814–1.019)
rs2240308 BB vs. BA+ AA PB 12 < 0.001 0.893 1.000 1.023(0.734–1.425) 0.96(0.823–1.119)
rs2240308 B vs. A HB 8 0.114 0.719 1.000 0.935(0.822–1.064) 0.984(0.901–1.075)
rs2240308 BB vs. AA HB 7 0.376 0.705 1.000 1.015(0.812–1.27) 1.04(0.849–1.273)
rs2240308 BA vs. AA HB 7 0.047 0.1 0.5 0.839(0.681–1.034) 0.919(0.808–1.045)
rs2240308 BB + BA vs. AA HB 7 0.043 0.128 0.64 0.855(0.699–1.046) 0.937(0.828–1.06)
rs2240308 BB vs. BA+ AA HB 7 0.684 0.444 1.000 1.075(0.897–1.287) 1.073(0.896–1.284)
rs2240308 B vs. A Colorectal Cancer 4 0.15 0.056 0.28 1.108(0.918–1.336) 1.116(0.997–1.249)
rs2240308 BB vs. AA Colorectal Cancer 4 0.192 0.031 0.155 1.314(0.903–1.911) 1.295(1.024–1.637)
rs2240308 BA vs. AA Colorectal Cancer 4 0.2 0.548 1.000 1.031(0.779–1.363) 1.057(0.882–1.266)
rs2240308 BB + BA vs. AA Colorectal Cancer 4 0.113 0.252 1.000 1.083(0.794–1.478) 1.105(0.931–1.312)
rs2240308 BB vs. BA+ AA Colorectal Cancer 4 0.563 0.036 0.18 1.241(1.011–1.524) 1.245(1.015–1.527)
rs2240308 B vs. A Prostate Cancer 2 0.099 0.452 1.000 0.828(0.507–1.353) 0.832(0.619–1.119)
rs2240308 BB vs. AA Prostate Cancer 2 0.509 0.987 1.000 1.004(0.539–1.869) 1.005(0.54–1.871)
rs2240308 BA vs. AA Prostate Cancer 2 0.088 0.127 0.635 0.555(0.26–1.183) 0.542(0.35–0.84)
rs2240308 BB + BA vs. AA Prostate Cancer 2 0.078 0.219 1.000 0.633(0.305–1.313) 0.62(0.412–0.934)
rs2240308 BB vs. BA+ AA Prostate Cancer 2 0.872 0.39 1.000 1.284(0.726–2.27) 1.284(0.726–2.27)
rs2240308 B vs. A Lung Cancer 6 < 0.001 0.176 0.88 0.854(0.678–1.074) 0.875(0.791–0.967)
rs2240308 BB vs. AA Lung Cancer 6 < 0.001 0.199 0.995 0.714(0.427–1.194) 0.776(0.626–0.962)
rs2240308 BA vs. AA Lung Cancer 6 0.317 0.069 0.345 0.868(0.736–1.023) 0.873(0.755–1.01)
rs2240308 BB + BA vs. AA Lung Cancer 6 0.022 0.218 1.000 0.827(0.648–1.056) 0.857(0.747–0.983)
rs2240308 BB vs. BA+ AA Lung Cancer 6 0.002 0.272 1.000 0.784(0.508–1.211) 0.817(0.669–0.998)
rs2240308 B vs. A Y 16 < 0.001 0.099 0.495 0.899(0.792–1.02) 0.928(0.866–0.994)
rs2240308 BB vs. AA Y 16 0.001 0.281 1.000 0.862(0.659–1.129) 0.904(0.78–1.048)
rs2240308 BA vs. AA Y 16 0.097 0.018 0.09 0.843(0.732–0.972) 0.874(0.786–0.971)
rs2240308 BB + BA vs. AA Y 16 0.008 0.03 0.15 0.838(0.714–0.983) 0.875(0.792–0.967)
rs2240308 BB vs. BA+ AA Y 16 0.011 0.604 1.000 0.945(0.761–1.172) 0.962(0.843–1.099)
rs2240308 B vs. A N 4 < 0.001 0.347 1.000 1.174(0.84–1.64) 1.056(0.944–1.182)
rs2240308 BB vs. AA N 3 < 0.001 0.21 1.000 1.961(0.684–5.618) 1.199(0.922–1.561)
rs2240308 BA vs. AA N 3 0.022 0.468 1.000 1.171(0.765–1.793) 1.066(0.88–1.292)
rs2240308 BB + BA vs. AA N 3 0.001 0.347 1.000 1.304(0.75–2.265) 1.095(0.915–1.31)
rs2240308 BB vs. BA+ AA N 3 < 0.001 0.243 1.000 1.648(0.713–3.81) 1.176(0.919–1.504)
rs35285779 B vs. A Overall 4 0.068 0.011 0.055 0.603(0.409–0.889) 0.632(0.496–0.806)
rs35285779 BB vs. AA Overall 4 0.378 0.038 0.19 0.43(0.194–0.955) 0.368(0.176–0.77)
rs35285779 BA vs. AA Overall 4 0.384 0.009 0.045* 0.685(0.513–0.915) 0.684(0.514–0.909)
rs35285779 BB + BA vs. AA Overall 4 0.155 0.001 0.005* 0.613(0.421–0.893) 0.639(0.486–0.839)
rs35285779 BB vs. BA+ AA Overall 4 0.448 0.017 0.085 0.473(0.219–1.025) 0.408(0.195–0.853)
rs35285779 B vs. A PB 2 0.172 0.034 0.17 0.691(0.442–1.08) 0.711(0.519–0.975)
rs35285779 BB vs. AA PB 2 0.352 0.145 0.725 0.452(0.147–1.388) 0.443(0.148–1.323)
rs35285779 BA vs. AA PB 2 0.434 0.102 0.51 0.741(0.517–1.062) 0.741(0.517–1.062)
rs35285779 BB + BA vs. AA PB 2 0.257 0.057 0.285 0.702(0.467–1.054) 0.713(0.504–1.01)
rs35285779 BB vs. BA+ AA PB 2 0.393 0.197 0.985 0.498(0.163–1.52) 0.488(0.164–1.452)
rs35285779 B vs. A HB 2 0.041 0.103 0.515 0.508(0.226–1.145) 0.535(0.365–0.783)
rs35285779 BB vs. AA HB 2 0.131 0.025 0.125 0.262(0.028–2.443) 0.317(0.116–0.868)
rs35285779 BA vs. AA HB 2 0.161 0.031 0.155 0.592(0.305–1.149) 0.598(0.375–0.954)
rs35285779 BB + BA vs. AA HB 2 0.081 0.104 0.52 0.519(0.236–1.144) 0.535(0.344–0.833)
rs35285779 BB vs. BA+ AA HB 2 0.16 0.043 0.215 0.311(0.041–2.355) 0.354(0.13–0.967)
rs35285779 B vs. A Lung Cancer 2 0.172 0.034 0.17 0.691(0.442–1.08) 0.711(0.519–0.975)
rs35285779 BB vs. AA Lung Cancer 2 0.352 0.145 0.725 0.452(0.147–1.388) 0.443(0.148–1.323)
rs35285779 BA vs. AA Lung Cancer 2 0.434 0.102 0.51 0.741(0.517–1.062) 0.741(0.517–1.062)
rs35285779 BB + BA vs. AA Lung Cancer 2 0.257 0.057 0.285 0.702(0.467–1.054) 0.713(0.504–1.01)
rs35285779 BB vs. BA+ AA Lung Cancer 2 0.393 0.197 0.985 0.498(0.163–1.52) 0.488(0.164–1.452)
rs7219582 B vs. A Overall 4 0.386 0.077 0.385 0.822(0.645–1.048) 0.82(0.659–1.021)
rs7219582 BA vs. AA Overall 4 0.035 0.538 1.000 0.75(0.3–1.873) 0.491(0.344–0.7)
rs7219582 BB + BA vs. AA Overall 4 0.045 0.538 1.000 0.758(0.313–1.833) 0.51(0.358–0.727)
rs7219582 B vs. A Lung Cancer 2 0.941 0.041 0.205 0.789(0.629–0.99) 0.789(0.629–0.99)
rs7219582 BA vs. AA Lung Cancer 2 0.399 < 0.001 < 0.001* 0.394(0.265–0.586) 0.394(0.265–0.585)
rs7219582 BB + BA vs. AA Lung Cancer 2 0.436 < 0.001 < 0.001* 0.414(0.278–0.614) 0.413(0.278–0.614)
rs9915936 B vs. A Overall 4 0.873 0.038 0.19 0.708(0.51–0.981) 0.707(0.51–0.981)
rs9915936 BA vs. AA Overall 4 0.668 0.014 0.07 0.634(0.44–0.914) 0.633(0.44–0.91)
rs9915936 BB + BA vs. AA Overall 4 0.775 0.021 0.105 0.662(0.466–0.94) 0.661(0.466–0.939)
rs9915936 B vs. A PB 2 0.806 0.034 0.17 0.667(0.459–0.971) 0.667(0.459–0.97)
rs9915936 BA vs. AA PB 2 0.548 0.009 0.045* 0.567(0.369–0.871) 0.566(0.369–0.87)
rs9915936 BB + BA vs. AA PB 2 0.669 0.016 0.08 0.607(0.404–0.913) 0.607(0.404–0.912)
rs9915936 B vs. A HB 2 0.619 0.646 1.000 0.855(0.436–1.677) 0.854(0.436–1.674)
rs9915936 BA vs. AA HB 2 0.608 0.637 1.000 0.848(0.425–1.692) 0.847(0.425–1.689)
rs9915936 BB + BA vs. AA HB 2 0.608 0.637 1.000 0.848(0.425–1.692) 0.847(0.425–1.689)
rs9915936 B vs. A Lung Cancer 2 0.806 0.034 0.17 0.667(0.459–0.971) 0.667(0.459–0.97)
rs9915936 BA vs. AA Lung Cancer 2 0.548 0.009 0.045* 0.567(0.369–0.871) 0.566(0.369–0.87)
rs9915936 BB + BA vs. AA Lung Cancer 2 0.669 0.016 0.08 0.607(0.404–0.913) 0.607(0.404–0.912)
  1. PH P value of Q test for heterogeneity test, PZ P value of meta-analysis, PAdjust Adjust PZ value by Bonferroni corrections, PAdjust = PZ * 5, P-B Population based, HWE Hardy Weinberg Equilibrium, Y polymorphisms conformed to HWE in the control group, N polymorphisms didn’t conform to HWE in the control group
  2. * P value less than 0.05 was considered as statistically significant
\